论文部分内容阅读
背景与目的:MUC1基因在胃癌、卵巢癌、多发性骨髓瘤、恶性淋巴瘤等肿瘤中有表达,在急性白血病患者中有较高的表达。但MUC1基因和多药耐药基因(MDR1)相互关系以及两者的表达与急性白血病治疗效果的关系尚有待探讨。本研究拟探讨MUC1基因与MDR1基因表达及其与非M3型急性白血病患者治疗效果的关系。方法:应用逆转录鄄聚合酶链反应(RT鄄PCR)法检测34例初治非M3型急性白血病患者MUC1和MDR1的表达,并观察两种基因表达及其与临床疗效的关系。结果:34例初治非M3型急性白血病患者中MUC1基因阳性率为50%,MDR1基因阳性率为29.4%。MUC1基因阳性患者的MDR1阳性率为52.9%,明显高于MUC1阴性者的5.9%(P=0.003)。MUC1基因阴性者完全缓解(CR)率达94.1%,阳性患者CR率52.9%,两组有显著性差异(P<0.05);MDR1基因阴性者CR率为91.7%,明显高于阳性患者的50.0%(P<0.05)。MUC1基因和MDR1基因均阳性者CR率为55.6%,MUC1基因和MDR1基因均阴性者16例,全部获得CR。结论:非M3型急性白血病MUC1基因阳性者MDR1基因表达率较高,MUC1基因及MDR1基因均为阴性者治疗缓解率高。提示联合检测MUC1基因和MDR1基因对判断初治非M3型急性白血病的疗效有良好的预测作用,可作为临床判断疗效的一项有意义的指标。
BACKGROUND & AIM: MUC1 gene is expressed in tumors of gastric cancer, ovarian cancer, multiple myeloma and malignant lymphoma, and is highly expressed in patients with acute leukemia. However, the relationship between MUC1 gene and multidrug resistance gene (MDR1) and the relationship between the expression of MUC1 and acute leukemia remains unclear. This study was to investigate the relationship between MUC1 gene and MDR1 gene expression and the therapeutic effect of non-M3 acute leukemia patients. Methods: The expression of MUC1 and MDR1 in 34 untreated non-M3 acute leukemia patients was detected by reverse transcriptase-polymerase chain reaction (RT-PCR), and the relationship between them and the clinical efficacy was observed. Results: The positive rate of MUC1 gene in 34 patients with non-M3 acute leukemia was 50%, and the positive rate of MDR1 gene was 29.4%. The positive rate of MDR1 in MUC1 positive patients was 52.9%, which was significantly higher than that in MUC1 negative patients (5.9%, P = 0.003). The complete remission (CR) rate was 94.1% in MUC1 negative patients and 52.9% in positive patients (P <0.05). The CR rate of MDR1 negative patients was 91.7%, which was significantly higher than that of positive patients % (P <0.05). CR rate of MUC1 gene and MDR1 gene were 55.6%, 16 cases were both MUC1 gene and MDR1 gene were negative, CR was all obtained. Conclusion: The positive rate of MDR1 gene expression in non-M3 acute leukemia patients with MUC1 gene is high, while both MUC1 gene and MDR1 gene are negative. These results suggest that the combined detection of MUC1 gene and MDR1 gene may be a good predictor of the curative effect of untreated non-M3 acute leukemia, which may be used as a meaningful indicator of clinical efficacy.